hit counter
Avinger, Inc. (AVGR) Stock News Sentiment & Price - Sentifly
AVGR - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Avinger, Inc. (AVGR)

USA
Medical Appliances & Equipment
NASDAQ
AVGR Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AVGR Latest news
Accesswire
Neutral
Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA
2021-10-07 08:45

Study Outcomes Demonstrate Safety and Efficacy of Pantheris for Treatment of In-Stent Restenosis REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that clinical data from the INSIGHT study were presented during the Late-Breaking Clinical Trials session at the VIVA (Vascular InterVentional Advances) conference in Las Vegas. The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger's Pantheris image-guided atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries.

Accesswire
Neutral
Avinger To Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
2021-09-08 08:45

REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will participate in investor meetings September 13-15, 2021 as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

Accesswire
Neutral
Avinger OCT-Guided Technologies Featured at AMP 2021
2021-08-16 08:00

REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced presentations featuring the Company's Lumivascular, OCT-guided, technologies at the annual AMP (Amputation Prevention Symposium) conference occurring last week. AMP focuses on education and technologies for treating critical limb ischemia (CLI), an advanced stage of PAD, in patients facing a life-altering amputation.

Seeking Alpha
Neutral
Avinger, Inc. (AVGR) CEO Jeff Soinski on Q2 2021 Results - Earnings Call Transcript
2021-08-10 20:08

Avinger, Inc. (AVGR) CEO Jeff Soinski on Q2 2021 Results - Earnings Call Transcript

Benzinga
Positive
Avinger: Q2 Earnings Insights
2021-08-10 16:35

Shares of Avinger (NASDAQ:AVGR) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 77.78% year over year to ($0.04), which were in line with the estimate of ($0.04).

Accesswire
Neutral
Avinger Reports Second Quarter 2021 Financial Results
2021-08-10 16:01

Pantheris Sales and Tigereye™ Expansion Drive 91% Year-Over-Year Revenue Growth REDWOOD CITY, CA / ACCESSWIRE / August 10, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Revenue increased 91% year-over-year to $2.8 million, fueled by Pantheris sales growth and new Tigereye CTO sales Record Pantheris SV revenue reflects strong market adoption of Avinger's small-vessel catheter, primarily used in below-the-knee (BTK) applications Image-guided CTO revenue increased 114% year-over-year, driven by Tigereye launch at more than 40 sites Gross margin increased to 36% as Avinger scales its operations Opened more than 30 new Lumivascular accounts in the last 12 months on increased market demand for Avinger's highly differentiated technology Filed

Benzinga
Neutral
Earnings Outlook For Avinger
2021-08-09 10:45

Avinger (NASDAQ:AVGR) releases its next round of earnings this Tuesday, August 10. Here is Benzinga's essential guide to Avinger's Q2 earnings report.

Accesswire
Neutral
Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console
2021-08-09 07:30

Smaller Footprint, Improved User Experience and Lower Cost to Drive Adoption REDWOOD CITY, CA / ACCESSWIRE / August 9, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console. "Avinger's Lightbox 3 represents an important leap forward in imaging, portability and capability," commented Jeff Soinski, Avinger's President and CEO.

Accesswire
Neutral
Avinger to Announce Second Quarter 2021 Results on August 10, 2021
2021-07-27 16:00

REDWOOD CITY, CA / ACCESSWIRE / July 27, 2021 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2021 after the close of trading on Tuesday, August 10, 2021. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Benzinga
Positive
Avinger Files US Application For New Pantheris In-Stent Restenosis Indication
2021-07-06 10:26

Avinger Inc (NASDAQ: AVGR) has submitted a 510(k) application to the FDA for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries. To submission is based on the INSIGHT trial that evaluated the safety and effectiveness of the Pantheris atherectomy system for treating in-stent restenosis in lower extremity arteries.

Loading more news...